Mitchell Gold, a major owner of Nivalis Therapeutics, Inc. and Nivalis Therapeutics, Inc.'s Executive Chairman and CEO and a director of the company, just received 70,000 options from the company. The strike price of the options received was $11.31, and these expire on January 01, 2028. Gold now owns at least 70,000 options on the company.
Some additional info was provided as follows:
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter.
The above information was disclosed i n a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Nivalis Therapeutics, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareWe... - Aug. 9, 2018
Nivalis Therapeutics, Inc.'s See Remarks just declared ownership of no shares of Nivalis Therapeutics, Inc. - Aug. 8, 2018
Nivalis Therapeutics, Inc.'s See Remarks was just granted 150,000 options - Aug. 8, 2018
Nivalis Therapeutics: Alpine Immune Sciences Strengthens Leadership Team With Appointment Of Mark Litton As President And Chief Operating Officer - Aug. 6, 2018